학술논문
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Document Type
Article
Author
Carbone, D.P.; Ciuleanu, T.-E.; Schenker, M.; Cobo, M.; Bordenave, S.; Juan-Vidal, O.; Menezes, J.; Reinmuth, N.; Richardet, E.; Cheng, Y.; Mizutani, H.; Felip, E.; Zurawski, B.; Alexandru, A.; Paz-Ares, L.; Lu, S.; John, T.; Zhang, X.; Mahmood, J.; Penrod, J.R.; Yuan, Y.; Lee, A.; Hu, N.; De, T.; Santi, I.; Reck, M.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 12 February 2024, 12(2))
Subject
Language
English
ISSN
20511426